Anti-SARS-CoV-2 IgG seroprevalence among non-vaccinated healthcare workers: a study from rural North India

Authors

  • Pratibha Mane Department of Microbiology, SHKM, GMC, Nuh, Nalhar, Haryana, India http://orcid.org/0000-0001-8410-2212
  • Jyoti Sangwan Department of Microbiology, SHKM, GMC, Nuh, Nalhar, Haryana, India
  • Kirti Lohan Department of Microbiology, SHKM, GMC, Nuh, Nalhar, Haryana, India

DOI:

https://doi.org/10.18203/2394-6040.ijcmph20212586

Keywords:

COVID-19, Health care worker, SARS-CoV-2, Seroprevalence

Abstract

Background: Coronavirus disease 2019 (COVID-19) is an infectious disease reported in China initially which spread around the world in no time affecting millions of people. It is caused by a new coronavirus (SARS-CoV-2 or 2019 n-CoV). The healthcare workers (HCW) are at increased risk of acquiring the disease as well as antibody response.

Methods: 457 health care workers (HCW) were recruited to give blood samples for anti-SARS CoV-2 IgG testing between September to October 2020.

Results: Of the 457 participants, IgG antibodies against SARS-CoV-2 were detected in 116 health care workers (25.4%). The anti-SARS-CoV-2 antibodies were detected maximally in HCWs involved in laboratory work. Around 4 % of health care workers were RT-PCR positive form whom IgG were detected in 15 individuals (71.4%) only.

Conclusions: The study concludes a higher prevalence among health care workers involved with patient’s samples and laboratory.

References

Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020;71(16):2027-34.

Ioannidis JPA. Coronavirus disease 2019: The harms of exaggerated information and non-evidence-based measures. Eur J Clin Invest. 2020;50(4):13222.

Thienemann F, Pinto F, Grobbee DE, Boehm M, Bazargani N, Ge J, et al. World Heart Federation Briefing on Prevention: Coronavirus Disease 2019 (COVID-19) in Low-Income Countries. Glob Heart. 2020;15(1):31.

Unnithan PS. Kerala reports first confirmed coronavirus case in India, 2020. Available at: ndiatoday.in/india/story/keralareportsfirstconfirmed-novel-coronavirus-case-in-india. Accessed on 18 May 2021.

Bhatnagar T, Murhekar MV, Soneja M, Gupta N, Giri S, Wig N, et al. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use. Indian J Med Res. 2020;151(2):184-9.

Riddell S, Goldie S, Hill A, Eagles D, Drew TW. The effect of temperature on persistence of SARS-CoV-2 on common surfaces. Virol J. 2020;17(1):145.

Moncunill G, Mayor A, Santano R, Jimenez A, Vidal M, Tortajada M, et al. SARS-CoV-2 Seroprevalence and Antibody Kinetics Among Health Care Workers in a Spanish Hospital After 3 Months of Follow-up. J Infect Dis. 2021;223(1):62-71.

Singhal T, Shah S, Naik R, Kazi A, Thakkar P. Prevalence of COVID-19 antibodies in healthcare workers at the peak of the pandemic in Mumbai, India: A preliminary study. Indian J Med Microbiol. 2020;38(3):461-3.

Shields A, Faustini SE, Perez TM, Jossi S, Aldera E, Allen JD, et al. SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional study. Thorax. 2020;75(12):1089-94.

Bulchandani VB, Shivam S, Moudgalya S, Sondhi SL. Digital herd immunity and COVID-19. Phys Biol. 2021.

Health Department Haryana. Seroprevalence of anti SARS- Cov-2 IgG antibodies in Haryana, India: A population based cross sectional study, 2020. Available at: http://nhmharyana.gov.in/WriteRead Data/userfiles/file/CoronaVirus/Final%20report%20Sero%20Survey0409. Accessed on 18 May 2021.

Siddiqui S, Naushin S, Pradhan S, Misra A, Tyagi A, Looma M, et al. SARS-CoV-2 antibody seroprevalence and stability in a tertiary care hospital-setting. Medrxiv. 2020.

Bhadade R, Harde M, Souza R, Kasbe A, Deshpande C, Dave S, et al. Appraisal of Critically Ill COVID-19 Patients at a Dedicated COVID Hospital. J Assoc Physicians India. 2020;68(9):14-9.

Wellinghausen N, Plonne D, Voss M, Ivanova R, Frodl R, Deininger S. SARS-CoV-2-IgG response is different in COVID-19 outpatients and asymptomatic contact persons. J Clin Virol. 2020;130:104542.

Goenka M, Afzalpurkar S, Goenka U, Das SS, Mukherjee M, Jajodia S, et al. Seroprevalence of COVID-19 Amongst Health Care Workers in a Tertiary Care Hospital of a Metropolitan City from India. J Assoc Physicians India. 2020;68(11):14-9.

Peeling RW, Wedderburn CJ, Garcia PJ, Boeras D, Fongwen N, Nkengasong J, Sall A, et al. Serology testing in the COVID-19 pandemic response. Lancet Infect Dis. 2020;20(9):245-9.

Gousseff M, Penot P, Gallay L, Batisse D, Benech N, Bouiller K, et al. Clinical recurrences of COVID-19 symptoms after recovery: Viral relapse, reinfection or inflammatory rebound?. J Infect. 2020;81(5):816-846.

Downloads

Published

2021-06-25

How to Cite

Mane, P., Sangwan, J., & Lohan, K. (2021). Anti-SARS-CoV-2 IgG seroprevalence among non-vaccinated healthcare workers: a study from rural North India. International Journal Of Community Medicine And Public Health, 8(7), 3348–3351. https://doi.org/10.18203/2394-6040.ijcmph20212586

Issue

Section

Original Research Articles